Literature DB >> 31862560

Encapsulating curcumin in ethylene diamine-β-cyclodextrin nanoparticle improves topical cornea delivery.

Chi-Hsien Liu1, Guan-Wei Lee2, Wei-Chi Wu3, Chun-Chao Wang4.   

Abstract

Curcumin is a powerful scavenger of reactive oxygen species and could prevent the corneal cells from oxidative damage. However, the clinical efficacy of curcumin is limited by its low aqueous solubility and stability, leading to poor bioavailability. β-cyclodextrin, with a hydrophilic surface and a hydrophobic cavity and self-assembling properties, can form inclusion complexes with lipophilic drugs such as curcumin for ocular delivery. We synthesized ethylene diamine (EDA)-modified β-cyclodextrin and prepared the curcumin complexation using the solvent evaporation method. The EDA-β-cyclodextrin provided a better thermodynamic stability and higher complex yield for curcumin complexes, compared to β-cyclodextrin, which were demonstrated on the analysis of their van't Hoff plots and phase solubility diagrams. We characterized EDA-β-cyclodextrin curcumin nanoparticles and determined that the EDA modified β-cyclodextrin is a more suitable carrier than parental β-cyclodextrin, using FT-IR, XRD, TEM, and analyses of solubility and storage stability. In addition, the curcumin-EDA-β-cyclodextrin nanoparticles had better in vitro corneal penetration and 3 -h cumulative flux in a porcine cornea experiment, and displayed an improved biocompatibility, confirmed by the histological examination of porcine corneas and cell viability of bovine corneal epithelial cells. These results together revealed a role of EDA modification in the β-cyclodextrin carrier, including the improvement of curcumin complex formation, thermodynamic properties, cytotoxicity, and the in vitro corneal penetration. The EDA-β-cyclodextrin inclusion can provide curcumin a higher degree of aqueous solubility and corneal permeability.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Curcumin; Ethylene diamine; Nanoparticles; Ocular delivery; β-cyclodextrin

Mesh:

Substances:

Year:  2019        PMID: 31862560     DOI: 10.1016/j.colsurfb.2019.110726

Source DB:  PubMed          Journal:  Colloids Surf B Biointerfaces        ISSN: 0927-7765            Impact factor:   5.268


  6 in total

1.  Curcumin-Loaded Mesenchymal Stem Cell-Derived Exosomes Efficiently Attenuate Proliferation and Inflammatory Response in Rheumatoid Arthritis Fibroblast-Like Synoviocytes.

Authors:  Xinghong He; Chong Zhang; Soumaye Amirsaadat; Abduladheem Turki Jalil; Mustafa M Kadhim; Mozhgan Abasi; Younes Pilehvar
Journal:  Appl Biochem Biotechnol       Date:  2022-08-06       Impact factor: 3.094

Review 2.  Antimicrobial Peptide Expression at the Ocular Surface and Their Therapeutic Use in the Treatment of Microbial Keratitis.

Authors:  Allison H Shannon; Sara A Adelman; Erin A Hisey; Sanskruti S Potnis; Vanessa Rozo; Madeline W Yung; Jennifer Y Li; Christopher J Murphy; Sara M Thomasy; Brian C Leonard
Journal:  Front Microbiol       Date:  2022-06-02       Impact factor: 6.064

3.  Tetraethylenepentamine-Coated β Cyclodextrin Nanoparticles for Dual DNA and siRNA Delivery.

Authors:  Chi-Hsien Liu; Pei-Yin Shih; Cheng-Han Lin; Yi-Jun Chen; Wei-Chi Wu; Chun-Chao Wang
Journal:  Pharmaceutics       Date:  2022-04-23       Impact factor: 6.525

4.  Polysaccharide-Based Nanomaterials for Ocular Drug Delivery: A Perspective.

Authors:  Haozhe Yu; Wenyu Wu; Xiang Lin; Yun Feng
Journal:  Front Bioeng Biotechnol       Date:  2020-12-10

Review 5.  Recent Developments of Nanostructures for the Ocular Delivery of Natural Compounds.

Authors:  Malihe Sadat Razavi; Pedram Ebrahimnejad; Yousef Fatahi; Antony D'Emanuele; Rassoul Dinarvand
Journal:  Front Chem       Date:  2022-04-13       Impact factor: 5.545

Review 6.  Ocular Drug Delivery: Advancements and Innovations.

Authors:  Bo Tian; Evan Bilsbury; Sean Doherty; Sean Teebagy; Emma Wood; Wenqi Su; Guangping Gao; Haijiang Lin
Journal:  Pharmaceutics       Date:  2022-09-13       Impact factor: 6.525

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.